We are live on
!
Find out more
ARTA
A.R.T. Advisors Portfolio holdings
AUM
$1.79M
1-Year Est. Return
57.47%
This Fund
S&P 500
This Quarter
Est. Return
+1.41%
1 Year Est. Return
+57.47%
3 Year Est. Return
+81.79%
5 Year Est. Return
+178.88%
10 Year Est. Return
–
AUM
$2B
AUM Growth
-$231M
(-10%)
Cap. Flow
-$214M
Cap. Flow
% of AUM
-10.69%
Top 10 Holdings %
Top 10 Hldgs %
6.82%
Holding
1,904
New
580
Increased
368
Reduced
360
Closed
591
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$13.5M |
| 2 |
Amgen
AMGN
|
+$13.4M |
| 3 |
Charter Communications
CHTR
|
+$12M |
| 4 |
Amazon
AMZN
|
+$11M |
| 5 |
CELG
Celgene Corp
CELG
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$20M |
| 2 |
LNKD
LinkedIn Corporation
LNKD
|
+$19.3M |
| 3 |
Pfizer
PFE
|
+$19.2M |
| 4 |
Alkermes
ALKS
|
+$14.8M |
| 5 |
Visa
V
|
+$12.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 14.12% |
| 2 | Healthcare | 11.46% |
| 3 | Technology | 11.32% |
| 4 | Industrials | 11.2% |
| 5 | Materials | 8.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Inuvo
INUV
$16.5M
| $20K | ﹤0.01% |
1,443
+390
| +37% | +$6.85K |
|
|
LITS
1302
Lite Strategy Inc
LITS
$33M
| $20K | ﹤0.01% |
763
-2,921
| -79% | -$81.9K |
|
1303
Global Ship Lease
GSL
$1.56B
| $19K | ﹤0.01% |
1,907
-3,563
| -65% | -$43.3K |
|
1304
Verastem
VSTM
$549M
| $19K | ﹤0.01% |
1,237
-2,219
| -64% | -$39.1K |
|
|
ACGN
1305
DELISTED
Aceragen Inc
ACGN
| $19K | ﹤0.01% |
+94
| New | +$20.7K |
|
|
NURO
1306
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
| $18K | ﹤0.01% |
+18
| New | +$20.5K |
|
|
EVFM
1307
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $18K | ﹤0.01% |
212
-429
| -67% | -$38.4K |
|
|
KALV
1308
DELISTED
KalVista Pharmaceuticals
KALV
| $17K | ﹤0.01% |
+1,935
| New | +$22.4K |
|
|
OTIV
1309
DELISTED
OTI On Track Innovations Ltd
OTIV
| $15K | ﹤0.01% |
+16,683
| New | +$15.4K |
|
|
BSTG
1310
DELISTED
Biostage, Inc. Common Stock
BSTG
| $12K | ﹤0.01% |
+10,910
| New | +$17.6K |
|
|
MATN
1311
DELISTED
Mateon Therapeutics, Inc.
MATN
| $7K | ﹤0.01% |
+10,601
| New | +$7.51K |
|
1312
Aaon
AAON
$8.27B
| – | – |
-29,358
| Closed | -$548K |
|
1313
Apple
AAPL
$4.93T
| – | – |
-134,232
| Closed | -$3.66M |
|
1314
AbbVie
ABBV
$456B
| – | – |
-77,522
| Closed | -$4.43M |
|
1315
Ambev
ABEV
$47.4B
| – | – |
-231,943
| Closed | -$1.2M |
|
1316
Asbury Automotive
ABG
$4.22B
| – | – |
-20,770
| Closed | -$1.24M |
|
1317
Acadia Pharmaceuticals
ACAD
$4.4B
| – | – |
-155,645
| Closed | -$4.35M |
|
|
ADAP
1318
DELISTED
Adaptimmune Therapeutics
ADAP
| – | – |
-21,600
| Closed | -$175K |
|
1319
Adeia
ADEA
$2.85B
| – | – |
-193,963
| Closed | -$1.59M |
|
1320
Autodesk
ADSK
$47.9B
| – | – |
-35,788
| Closed | -$2.09M |
|
1321
Ameren
AEE
$31.1B
| – | – |
-40,024
| Closed | -$2M |
|
1322
AerCap
AER
$23.9B
| – | – |
-33,650
| Closed | -$1.3M |
|
1323
Aflac
AFL
$64.4B
| – | – |
-34,074
| Closed | -$1.07M |
|
|
AGEN
1324
Agenus
AGEN
$254M
| – | – |
-12,806
| Closed | -$1.04M |
|
1325
Alamos Gold
AGI
$12.4B
| – | – |
-11,198
| Closed | -$59K |
|
Similar funds
MA
FFIM
LC
YEPV
AAM
CCM
IR
IFC
A.R.T. Advisors's Q2 2016 Portfolio in Review
As of Q2 2016, A.R.T. Advisors held 1,904 positions worth $2B, down 10% from $2.24B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.
A.R.T. Advisors withdrew a net $214M in Q2 2016, closing 591 positions and reducing 360 holdings. Its most notable exit was Johnson & Johnson, an estimated $20M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 14% of assets, up from 13% a quarter earlier, followed by Healthcare and Technology.
Against the trend, A.R.T. Advisors opened a new position in Mastercard worth $12.4M.
- A.R.T. Advisors's largest Q2 2016 buy was Mastercard: 141,390 shares worth $12.4M.
- A.R.T. Advisors added most to Paramount Global Class B in Q2 2016, an estimated $8.3M increase.
- A.R.T. Advisors's biggest Q2 2016 reduction was Visa, cutting an estimated $12.8M.
- A.R.T. Advisors fully exited Johnson & Johnson in Q2 2016, selling an estimated $20M.
- A.R.T. Advisors's ten largest holdings make up 6.8% of its $2B portfolio in Q2 2016.
- A.R.T. Advisors opened 580 new positions and closed 591 in Q2 2016.
- A.R.T. Advisors's portfolio value fell 10% quarter-over-quarter to $2B.
Based on A.R.T. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.